Pharm-Rx Spironolactone USP

Product families

Other characteristics

Certifications & Compliance

United States Pharmacopeia (USP)

Markets

Healthcare & Pharma

Defination

Spironolactone contains NLT 97.0% and NMT 103.0% of spironolactone (C₂₄H₃₂O₄S), calculated on the dried basis.

Technology

Pharmaceuticals & Nutraceuticals

FDA Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Storage Information

Preserve in well-closed containers.

USP Reference Standards

USP Spironolactone RS; USP Spironolactone Related Compound A RS; 2′R)-3′,4′-Dihydro-5′H-spiro[androst-4,6-diene-17,2′- furan]-3,5′-dione. C₂₂H₂₈O₃ 340.46 USP Spironolactone Related Compound B RS; 2′R)-7α-(Acetylthio)-5′H-spiro[androst-4-ene-17,2′- furan]-3,5′-dione. C₂₄H₃₀O₄S 414.56; USP Spironolactone Related Compound C RS (2′R)-3′,4′-Dihydro-5′H-spiro[androst-4-ene-17,2′-furan]- 3,5′-dione. C₂₂H₃₀O₃ 342.47; USP Spironolactone Related Compound D RS (2′R)-7α-(Acetyldisulfanyl)-3′,4′-dihydro-5′Hspiro[ androst-4-ene-17,2′-furan]-3,5′-dione. C₂₄H₃₂O₄S₂ 448.64; USP Spironolactone Epimer Mixture RS; USP Spironolactone Related Compound C RS (2′RIt contains a mixture of approximately 39% of spironolactone and 56% of 7-epispironolactone: (2′R)-7β-(Acetylthio)-3′,4′-dihydro-5′H-spiro[androst-4- ene-17,2′-furan]-3,5′-dione. C24H32O4S 416.57)-3′,4′-Dihydro-5′H-spiro[androst-4-ene-17,2′-furan]- 3,5′-dione. C₂₂H₃₀O₃ 342.47; USP Spironolactone Related Compound I RS; S-[17α-(Ethoxymethyl)-17-hydroxy-3-oxoandrost-4-en- 7α-yl]ethanethioate. C₂₄H₃₆O₄S 420.61

Show in full

Certifications and Compliance

United States Pharmacopeia (USP)